Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures

Garth E Ringheim, Matthew Wampole, Kinsi Oberoi, Garth E Ringheim, Matthew Wampole, Kinsi Oberoi

Abstract

Clinical development of BTK kinase inhibitors for treating autoimmune diseases has lagged behind development of these drugs for treating cancers, due in part from concerns over the lack of selectivity and associated toxicity profiles of first generation drug candidates when used in the long term treatment of immune mediated diseases. Second generation BTK inhibitors have made great strides in limiting off-target activities for distantly related kinases, though they have had variable success at limiting cross-reactivity within the more closely related TEC family of kinases. We investigated the BTK specificity and toxicity profiles, drug properties, disease associated signaling pathways, clinical indications, and trial successes and failures for the 13 BTK inhibitor drug candidates tested in phase 2 or higher clinical trials representing 7 autoimmune and 2 inflammatory immune-mediated diseases. We focused on rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE) where the majority of BTK nonclinical and clinical studies have been reported, with additional information for pemphigus vulgaris (PV), Sjogren's disease (SJ), chronic spontaneous urticaria (CSU), graft versus host disease (GVHD), and asthma included where available. While improved BTK selectivity versus kinases outside the TEC family improved clinical toxicity profiles, less profile distinction was evident within the TEC family. Analysis of genetic associations of RA, MS, and SLE biomarkers with TEC family members revealed that BTK and TEC family members may not be drivers of disease. They are, however, mediators of signaling pathways associated with the pathophysiology of autoimmune diseases. BTK in particular may be associated with B cell and myeloid differentiation as well as autoantibody development implicated in immune mediated diseases. Successes in the clinic for treating RA, MS, PV, ITP, and GVHD, but not for SLE and SJ support the concept that BTK plays an important role in mediating pathogenic processes amenable to therapeutic intervention, depending on the disease. Based on the data collected in this study, we propose that current compound characteristics of BTK inhibitor drug candidates for the treatment of autoimmune diseases have achieved the selectivity, safety, and coverage requirements necessary to deliver therapeutic benefit.

Keywords: B cell; Bruton’s tyrosine kinase (BTK); Sjogren’s syndrome; autoimmune disease; multiple sclerosis; pemphigus vulgaris; rheumatoid arthritis; systemic lupus erythematosus.

Conflict of interest statement

Author GER was employed by company Eisai Inc. MW and KO are employed by Clarivate that owns the commercial database products used in the research presented.

Copyright © 2021 Ringheim, Wampole and Oberoi.

Figures

Figure 1
Figure 1
“Chemotaxis_CXCL12/CXCR4-induced chemotaxis of immune cells”. Illustration generated with MetaCore pathway analysis tool indicating the involvement of BTK and disease biomarkers to induce chemotactic response in immune cells leading to cell adhesion and cell migration. Data overlaid onto the pathway map are represented as thermometers which typically would indicate the level of over/under expression of a gene. Thermometer 1 represents SJ biomarkers, thermometer 2 represents MS biomarkers, thermometer 3 represents SLE biomarkers, and thermometer 4 represents RA biomarkers. For demonstration purposes, each of these biomarkers was given a value of 1.

References

    1. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. . Efficacy of B-Cell-Targeted Therapy With Rituximab in Patients With Rheumatoid Arthritis. N Engl J Med (2004) 350(25):2572–81. doi: 10.1056/NEJMoa032534
    1. Lee YH, Bae SC, Song GG. The Efficacy and Safety of Rituximab for the Treatment of Active Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Rheumatol Int (2011) 31(11):1493–9. doi: 10.1007/s00296-010-1526-y
    1. Chan VS, Tsang HH, Tam RC, Lu L, Lau CS. B-Cell-Targeted Therapies in Systemic Lupus Erythematosus. Cell Mol Immunol (2013) 10(2):133–42. doi: 10.1038/cmi.2012.64
    1. DiGirolamo N, Visvanathan K, Lloyd A, Wakefield D. Expression of TNF-Alpha by Human Plasma Cells in Chronic Inflammation. J Leukocyte Biol (1997) 61(6):667–78. doi: 10.1002/jlb.61.6.667
    1. Harvey PR, Gordon C. B-Cell Targeted Therapies in Systemic Lupus Erythematosus: Successes and Challenges. BioDrugs (2013) 27(2):85–95. doi: 10.1007/s40259-013-0015-8
    1. Mok CC. Update on B-Cell Targeted Therapies for Systemic Lupus Erythematosus. Expert Opin Biol Ther (2014) 14(6):773–88. doi: 10.1517/14712598.2014.895810
    1. Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, et al. . Assessment of Rituximab’s Immunomodulatory Synovial Effects (ARISE Trial). 1: Clinical and Synovial Biomarker Results. Ann Rheum Dis (2008) 67(3):402–8. doi: 10.1136/ard.2007.074229
    1. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial Tissue Response to Rituximab: Mechanism of Action and Identification of Biomarkers of Response. Ann Rheum Dis (2008) 67(7):917–25. doi: 10.1136/ard.2007.080960
    1. Hiepe F, Dorner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-Lived Autoreactive Plasma Cells Drive Persistent Autoimmune Inflammation. Nat Rev Rheumatol (2011) 7(3):170–8. doi: 10.1038/nrrheum.2011.1
    1. Niiro H, Clark EA. Regulation of B-Cell Fate by Antigen-Receptor Signals. Nat Rev Immunol (2002) 2(12):945–56. doi: 10.1038/nri955
    1. Khan WN. Regulation of B Lymphocyte Development and Activation by Bruton’s Tyrosine Kinase. Immunol Res (2001) 23(2-3):147–56. doi: 10.1385/IR:23:2-3:147
    1. Mangla A, Khare A, Vineeth V, Panday NN, Mukhopadhyay A, Ravindran B, et al. . Pleiotropic Consequences of Bruton Tyrosine Kinase Deficiency in Myeloid Lineages Lead to Poor Inflammatory Responses. Blood (2004) 104(4):1191–7. doi: 10.1182/blood-2004-01-0207
    1. Rip J, de Bruijn MJW, Appelman MK, Pal Singh S, Hendriks RW, Corneth OBJ. Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease. Front Immunol (2019) 10:95. doi: 10.3389/fimmu.2019.00095
    1. Lopez-Herrera G, Vargas-Hernandez A, Gonzalez-Serrano ME, Berron-Ruiz L, Rodriguez-Alba JC, Espinosa-Rosales F, et al. . Bruton’s Tyrosine Kinase–an Integral Protein of B Cell Development That Also has an Essential Role in the Innate Immune System. J Leukoc Biol (2014) 95(2):243–50. doi: 10.1189/jlb.0513307
    1. de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, et al. . Bruton’s Tyrosine Kinase and Phospholipase Cgamma2 Mediate Chemokine-Controlled B Cell Migration and Homing. Immunity (2007) 26(1):93–104. doi: 10.1016/j.immuni.2006.11.012
    1. Kuehn HS, Radinger M, Brown JM, Ali K, Vanhaesebroeck B, Beaven MA, et al. . Btk-Dependent Rac Activation and Actin Rearrangement Following FcepsilonRI Aggregation Promotes Enhanced Chemotactic Responses of Mast Cells. J Cell Sci (2010) 123(Pt 15):2576–85. doi: 10.1242/jcs.071043
    1. Quek LS, Bolen J, Watson SP. A Role for Bruton’s Tyrosine Kinase (Btk) in Platelet Activation by Collagen. Curr Biol (1998) 8(20):1137–40. doi: 10.1016/S0960-9822(98)70471-3
    1. Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, et al. . Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals. Cell (2008) 132(5):794–806. doi: 10.1016/j.cell.2007.12.037
    1. Sterner RM, Hartono SP, Grande JP. The Pathogenesis of Lupus Nephritis. J Clin Cell Immunol (2014) 5:2. doi: 10.4172/2155-9899.1000205
    1. Lech M, Anders HJ. The Pathogenesis of Lupus Nephritis. J Am Soc Nephrol (2013) 24(9):1357–66. doi: 10.1681/ASN.2013010026
    1. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. . The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and Is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy. Proc Natl Acad Sci USA (2010) 107(29):13075–80. doi: 10.1073/pnas.1004594107
    1. Duarte DP, Lamontanara AJ, La Sala G, Jeong S, Sohn YK, Panjkovich A, et al. . Btk SH2-Kinase Interface Is Critical for Allosteric Kinase Activation and Its Targeting Inhibits B-Cell Neoplasms. Nat Commun (2020) 11(1):2319. doi: 10.1038/s41467-020-16128-5
    1. Smith CI, Islam TC, Mattsson PT, Mohamed AJ, Nore BF, Vihinen M. The Tec Family of Cytoplasmic Tyrosine Kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and Homologs in Other Species. Bioessays (2001) 23(5):436–46. doi: 10.1002/bies.1062
    1. Shah NH, Amacher JF, Nocka LM, Kuriyan J. The Src Module: An Ancient Scaffold in the Evolution of Cytoplasmic Tyrosine Kinases. Crit Rev Biochem Mol Biol (2018) 53(5):535–63. doi: 10.1080/10409238.2018.1495173
    1. Hantschel O, Superti-Furga G. Regulation of the C-Abl and Bcr-Abl Tyrosine Kinases. Nat Rev Mol Cell Biol (2004) 5(1):33–44. doi: 10.1038/nrm1280
    1. Shaw ML. Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects. Am J Manag Care (2020) 26(7 Spec No.):SP226–SP7. doi: 10.37765/ajmc.2020.88475
    1. Nikolsky Y, Kirillov E, Zuev R, Rakhmatulin E, Nikolskaya T. Functional Analysis of OMICs Data and Small Molecule Compounds in an Integrated “Knowledge-Based” Platform. In: Nikolsky Y, Bryant J, editors. Protein Networks and Pathway Analysis. Methods in Molecular Biology (Methods and Protocols). New York City, NY: Human Press; (2009). vol. 563:177–96. doi: 10.1007/978-1-60761-175-2_10
    1. Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, et al. . Op0233 Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (Gdc-0853), in Moderate to Severe Systemic Lupus Erythematosus in a Phase 2 Controlled Study. Ann Rheumatic Dis (2020) 79(Suppl 1):148.1–. doi: 10.1136/annrheumdis-2020-eular.2949
    1. Wallace DJ, Dorner T, Pisetsky D, Sanchez-Guerrero FJ, Kao A, Parsons-Rich D, et al. . Efficacy and Safety of Evobrutinib (M2951) in Adult Patients With Systemic Lupus Erythematosus Who Received Standard of Care Therapy: A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study. Arthritis Rheumatol (2020) 72(SUPPL 10):1711–3. doi: 10.1002/art.41538
    1. Waller EK, Miklos D, Cutler C, Arora M, Jagasia MH, Pusic I, et al. . Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biol Blood Marrow Transplant (2019) 25(10):2002–7. doi: 10.1016/j.bbmt.2019.06.023
    1. Watterson SH, De Lucca GV, Shi Q, Langevine CM, Liu Q, Batt DG, et al. . Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4H)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1H-Carbazole-8- Carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers. J Med Chem (2016) 59(19):9173–200. doi: 10.1021/acs.jmedchem.6b01088
    1. Gillooly KM, Pulicicchio C, Pattoli MA, Cheng L, Skala S, Heimrich EM, et al. . Bruton's Tyrosine Kinase Inhibitor BMS-986142 in Experimental Models of Rheumatoid Arthritis Enhances Efficacy of Agents Representing Clinical Standard-of-Care. PLoS One (2017) 12(7):e0181782. doi: 10.1371/journal.pone.0181782
    1. Watterson SH, Liu Q, Beaudoin Bertrand M, Batt DG, Li L, Pattoli MA, et al. . Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK). J Med Chem (2019) 62(7):3228–50. doi: 10.1021/acs.jmedchem.9b00167
    1. Ahmad S, Tino JA, Macor JE, Tebben AJ, Gong H, Liu Q, et al. . Indole Carboxamides Compounds Useful as Kinase Inhibitors. US Patent 9,688,629. Alexandria, VA: U.S. Patent and Trademark Office; (2014).
    1. Lannutti B, Covey T, Kaptein A, Johnson D, Stamatis J, Krejsa CM, et al. . Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate. WIPO Patent WO2017025814. Geneva, Switzerland: World Intellectual Property Organization; (2015).
    1. Vasudevan A, Wilson N, Frank K, Xu X, Friedman M, Hoemann M, et al. . eds. Considerations in the Generation of Covalent BTK Inhibitors. In: 19th RSC/SCI Med Chem Symposium [Conference Presentation]. Cambridge, United Kingdom: (2017). Available at: .
    1. Goess C, Graff C, Zhang TT, Preston G, McCarthy R, Perham M, et al. . eds. Efficacy of ABBV-105, A Selective and Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Multiple Models of Inflammation. In: Arthritis Rheumatol (2015) 67(suppl 10).
    1. Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, et al. . Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models. J Immunol (2019) 202(10):2888–906. doi: 10.4049/jimmunol.1800583
    1. Goutopoulos A. ed. Discovery of M2951: A Selective, Covalent Inhibitor of BTK for the Treatment of Autoimmune Diseases. In: 254th Am Chem Soc Natl Meet. Cambridge, MA: Medchem By Design 2017 Symposia; (2017). Available at: .
    1. Dellovade T. Inventormethods for Treating MS Using Pyrimidine and Pyridine Compounds With BTK Inhibitory Activity. US Patent 10, 716,788. Alexandria, VA: U.S. Patent and Trademark Office; (2015).
    1. Haselmayer P, Camps M, Liu-Bujalski L, Morandi F, Head J, Zimmerli S, et al. . THU0275 Pharmacodynamic Modeling of BTK Occupancy Versus Efficacy in RA and SLE Models Using the Novel Specific BTK Inhibitor M2951. Ann Rheum Dis (2016) 75:286–7. doi: 10.1136/annrheumdis-2016-eular.434251
    1. Young WB. ed. Discovery of GDC-0853: A Potent Selective BTK Inhibitor for the Treatment of Lupus and Rheumatoid Arthritis. In: 253rd Am Chem Soc Natl Meet. San Francisco, USA: (2017). Available at: .
    1. Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, et al. . Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development. J Med Chem (2018) 61(6):2227–45. doi: 10.1021/acs.jmedchem.7b01712
    1. Honigberg L, Verner EJ, Buggy JJ, Loury DJ, Chen W, inventors; Pharmacyclics, LLC, assignee . Inhibitors of Bruton’s Tyrosine Patent 8,735,404. Alexandria, VA: U.S. Patent and Trademark Office; (2006).
    1. Zhang X, Sheng X, Shen J, Zhang S, Sun W, Shen C, et al. . Discovery and Evaluation of Pyrazolo[3,4-D]Pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor. ACS Med Chem Lett (2020) 11(10):1863–8. doi: 10.1021/acsmedchemlett.9b00395
    1. Normant E, Gorelik L, Shmeis R, Le H, Nisch R, Miskin HP, et al. . eds. TG-1701 a Novel, Orally Available, and Covalently-Bound Btk Inhibitor. In: 23rd Congr Eur Hematol Assoc (EHA). Stockholm, Sweden: (2018). Available at: .
    1. Zhang C, Pei H, He J, Zhu J, Li W, Niu T, et al. . Design, Synthesis and Evaluation of Novel 7H-Pyrrolo[2,3-D]Pyrimidin-4-Amine Derivatives as Potent, Selective and Reversible Bruton’s Tyrosine Kinase (BTK) Inhibitors for the Treatment of Rheumatoid Arthritis. Eur J Med Chem (2019) 169:121–43. doi: 10.1016/j.ejmech.2019.02.077
    1. Kim YY, Park KT, Jang SY, Lee KH, Byun JY, Suh KH, et al. . HM71224, A Selective Bruton's Tyrosine Kinase Inhibitor, Attenuates the Development of Murine Lupus. Arthritis Res Ther (2017) 19(1):211. doi: 10.1186/s13075-017-1402-1
    1. Park JK, Byun JY, Park JA, Kim YY, Lee YJ, Oh JI, et al. . HM71224, a Novel Bruton’s Tyrosine Kinase Inhibitor, Suppresses B Cell and Monocyte Activation and Ameliorates Arthritis in a Mouse Model: A Potential Drug for Rheumatoid Arthritis. Arthritis Res Ther (2016) 18:91. doi: 10.1186/s13075-016-0988-z
    1. Jang SY, Kim YY, Song JY, Lee YM, Kim YH, Suh KH. HM71224, A Novel BTK Inhibitor Demonstrates Potent Activities in Rodent Models of Arthritis. Ann Rheum Dis (2014) 73(Suppl 2):518–9. doi: 10.1136/annrheumdis-2014-eular.3059
    1. Cenni B, End P, Cabanski M, Jakab A, Funhoff E, Kistowska M. LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren’s Syndrome. Arthritis Rheumatol (2019) 71(suppl 10).
    1. Angst D, Gessier F, Janser P, Vulpetti A, Walchli R, Beerli C, et al. . Discovery of LOU064 (Remibrutinib), A Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. J Med Chem (2020) 63(10):5102–18. doi: 10.1021/acs.jmedchem.9b01916
    1. Hill RJ, Bradshaw JM, Bisconte A, Tam D, Owens TD, Brameld KA, et al. . Preclinical Characterization of PRN1008, A Novel Reversible Covalent Inhibitor of BTK that Shows Efficacy in a Rat Model of Collagen-Induced Arthritis. Ann Rheum Dis (2015) 74(Suppl 2):216–7. doi: 10.1136/annrheumdis-2015-eular.3641
    1. Langrish CL, Bradshaw JM, Owens TD, Campbell RL, Francesco MR, Karr DE, et al. . PRN1008, A Reversible Covalent BTK Inhibitor in Clinical Development for Immune Thrombocytopenic Purpura. Blood (2017) 130(Supp 1):1052.
    1. Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, et al. . Inhibition of Btk With CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans. J Pharmacol Exp Ther (2013) 346(2):219–28. doi: 10.1124/jpet.113.203489
    1. Karp RE, Evans E, Aslanian S, Chaturvedi P, Mazdiyasni H, Westlin W. Inhibition of Btk with AVL-292 Translates to Protective Activity In Animal Models of Rheumatoid Arthritis. In: 16th Bienn Int Conf Inflamm Res Assoc. Chantilly, VA, USA: (2010) 59:263–304. doi: 10.1007/s00011-010-0235-z
    1. Westlin WFI, Raab EE, Horowitz ZD, Kasserra CE, Beebe L, Palmisano M, et al. . Methods of Treating a Bruton’s Tyrosine Kinase Disease or Disorder. WIPO Patent WO2014039452. Geneva, Switzerland: World Intellectual Property Organization; (2012).
    1. Ariza Y, Yoshizawa T, Ueda Y, Murata M, Kawabata K. eds. ONO-4059 - A Highly Potent and Dual Oral Inhibitor of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase: Improves Anti-Nuclear Antibodies-Mediated SLE in Mice. In: 78th Annu Sci Meet Am Coll Rheumatol. Boston, USA: (2012). Available at: .
    1. Di Paolo JF, Franci C, Gentzler T, Murray B, Li L. eds. Targeting the BTK-JAK Axis in Preclinical Models of Rat Collagen-Induced Arthritis With GS-4059 in Combination With a JAK Inhibitor. Arthritis Rheumatol (2016) 68(suppl 10).
    1. Yoshizawa T, Ariza Y, Ueda Y, Hotta S, Narita M, Kawabata K, et al. . eds. Development of a Bruton’s Tyrosine Kinase (BTK) Inhibitor, ONO-4059: Efficacy in a Collagen Induced Arthritis (CIA) Model Indicates Potential Treatment for Rheumatoid Arthritis (RA). In: 76th Annu Sci Meet Am Coll Rheumatol. Washington, D.C., USA: (2012). Available at: .
    1. Francesco MR, Wong M, LaStant J, Finkle D, Loewenstein N, Macsata R, et al. . PRN2246, a Potent and Selective Blood Brain Barrier Penetrating BTK Inhibitor, Exhibits Efficacy in Central Nervous System Immunity. Stockholm, Sweden: ECTRIMS; (2017) Poster 989. Available at: .
    1. Zi F, Yu L, Shi Q, Tang A, Cheng J. Ibrutinib in CLL/SLL: From Bench to Bedside (Review). Oncol Rep (2019) 42(6):2213–27. doi: 10.3892/or.2019.7364
    1. Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. . Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy. Blood (2017) 130(21):2243–50. doi: 10.1182/blood-2017-07-793786
    1. Liclican A, Serafini L, Xing W, Czerwieniec G, Steiner B, Wang T, et al. . Biochemical Characterization of Tirabrutinib and Other Irreversible Inhibitors of Bruton’s Tyrosine Kinase Reveals Differences in On - and Off - Target Inhibition. Biochim Biophys Acta Gen Subj (2020) 1864(4):129531. doi: 10.1016/j.bbagen.2020.129531
    1. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. . Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2016) 374(4):323–32. doi: 10.1056/NEJMoa1509981
    1. Alsadhan A, Cheung J, Gulrajani M, Gaglione EM, Nierman P, Hamdy A, et al. . Pharmacodynamic Analysis of BTK Inhibition in Patients With Chronic Lymphocytic Leukemia Treated With Acalabrutinib. Clin Cancer Res (2020) 26(12):2800–9. doi: 10.1158/1078-0432.CCR-19-3505
    1. Schafer PH, Kivitz AJ, Ma J, Korish S, Sutherland D, Li L, et al. . Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients With Rheumatoid Arthritis: Results From a Mechanistic Study. Rheumatol Ther (2020) 7(1):101–19. doi: 10.1007/s40744-019-00182-7
    1. Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L, et al. . Mutation of Unique Region of Bruton’s Tyrosine Kinase in Immunodeficient XID Mice. Science (1993) 261(5119):358–61. doi: 10.1126/science.8332901
    1. Khan WN, Alt FW, Gerstein RM, Malynn BA, Larsson I, Rathbun G, et al. . Defective B Cell Development and Function in Btk-Deficient Mice. Immunity (1995) 3(3):283–99. doi: 10.1016/1074-7613(95)90114-0
    1. Thomas JD, Sideras P, Smith CI, Vorechovsky I, Chapman V, Paul WE. Colocalization of X-Linked Agammaglobulinemia and X-Linked Immunodeficiency Genes. Science (1993) 261(5119):355–8. doi: 10.1126/science.8332900
    1. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. . Deficient Expression of a B Cell Cytoplasmic Tyrosine Kinase in Human X-Linked Agammaglobulinemia. Cell (1993) 72(2):279–90. doi: 10.1016/0092-8674(93)90667-F
    1. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, et al. . The Gene Involved in X-Linked Agammaglobulinaemia Is a Member of the Src Family of Protein-Tyrosine Kinases. Nature (1993) 361(6409):226–33. doi: 10.1038/361226a0
    1. Whyburn LR, Halcomb KE, Contreras CM, Lowell CA, Witte ON, Satterthwaite AB. Reduced Dosage of Bruton’s Tyrosine Kinase Uncouples B Cell Hyperresponsiveness From Autoimmunity in Lyn-/- Mice. J Immunol (2003) 171(4):1850–8. doi: 10.4049/jimmunol.171.4.1850
    1. Cohen S, Tuckwell K, Katsumoto TR, Zhao R, Galanter J, Lee C, et al. . Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study). Arthritis Rheumatol (2020) 72(9):1435–46. doi: 10.1002/art.41275
    1. Dennis G, Jr, Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, et al. . Synovial Phenotypes in Rheumatoid Arthritis Correlate With Response to Biologic Therapeutics. Arthritis Res Ther (2014) 16(2):R90. doi: 10.1186/ar4555
    1. Nyhoff LE, Barron BL, Johnson EM, Bonami RH, Maseda D, Fensterheim BA, et al. . Bruton’s Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice But Fails to Block Immune Complex-Mediated Inflammatory Arthritis. Arthritis Rheumatol (2016) 68(8):1856–68. doi: 10.1002/art.39657
    1. Cambridge G, Perry HC, Nogueira L, Serre G, Parsons HM, de la Torre I, et al. . The Effect of B-Cell Depletion Therapy on Serological Evidence of B-Cell and Plasmablast Activation in Patients With Rheumatoid Arthritis Over Multiple Cycles of Rituximab Treatment. J Autoimmun (2014) 50:67–76. doi: 10.1016/j.jaut.2013.12.002
    1. Trouvin AP, Jacquot S, Grigioni S, Curis E, Dedreux I, Roucheux A, et al. . Usefulness of Monitoring of B Cell Depletion in Rituximab-Treated Rheumatoid Arthritis Patients in Order to Predict Clinical Relapse: A Prospective Observational Study. Clin Exp Immunol (2015) 180(1):11–8. doi: 10.1111/cei.12481
    1. Li R, Patterson KR, Bar-Or A. Reassessing B Cell Contributions in Multiple Sclerosis. Nat Immunol (2018) 19(7):696–707. doi: 10.1038/s41590-018-0135-x
    1. Torke S, Weber MS. Inhibition of Bruton s Tyrosine Kinase as a Novel Therapeutic Approach in Multiple Sclerosis. Expert Opin Investig Drugs (2020) 29(10):1143–50. doi: 10.1080/13543784.2020.1807934
    1. Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, et al. . Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. N Engl J Med (2019) 380(25):2406–17. doi: 10.1056/NEJMoa1901981
    1. Sanofi Brain-Penetrant BTK Inhibitor Significantly Reduced Disease Activity in Phase 2 Trial in Relapsing Multiple Sclerosis 2020. Available at: .
    1. Di Zenzo G, Amber KT, Sayar BS, Muller EJ, Borradori L. Immune Response in Pemphigus and Beyond: Progresses and Emerging Concepts. Semin Immunopathol (2016) 38(1):57–74. doi: 10.1007/s00281-015-0541-1
    1. Murrell DF, Stavroupoulos P, Patsatsi A, Baum S, Roussaki A, Kern JS, et al. . Clinical Endpoint Analysis of the Believe-PV Phase 2 Study of PRN1008 in Pemphigus [PDF]. (2018). Available at: .
    1. McMillan R. Autoantibodies and Autoantigens in Chronic Immune Thrombocytopenic Purpura. Semin Hematol (2000) 37(3):239–48. doi: 10.1016/S0037-1963(00)90102-1
    1. Cooper N, Thomas D, Neale A, Burns R, Bandman O, McDonald V, et al. . Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients With Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia. Blood (2019) 134(Supplement_1):87–. doi: 10.1182/blood-2019-122336
    1. Bracken SJ, Abraham S, MacLeod AS. Autoimmune Theories of Chronic Spontaneous Urticaria. Front Immunol (2019) 10:627. doi: 10.3389/fimmu.2019.00627
    1. Kaul M, End P, Cabanski M, Schuhler C, Jakab A, Kistowska M, et al. . Remibrutinib (LOU064): A Selective Potent Oral BTK Inhibitor With Promising Clinical Safety and Pharmacodynamics in a Randomized Phase I Trial. Clin Transl Sci (2021) 14(5):1756–68. doi: 10.1111/cts.13005
    1. Parisis D, Chivasso C, Perret J, Soyfoo MS, Delporte C. Current State of Knowledge on Primary Sjogren’s Syndrome, an Autoimmune Exocrinopathy. J Clin Med (2020) 9(7):2299. doi: 10.3390/jcm9072299
    1. Ma K, Du W, Wang X, Yuan S, Cai X, Liu D, et al. . Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus. Int J Mol Sci (2019) 20(23):6021. doi: 10.3390/ijms20236021
    1. Corneth OBJ, Verstappen GMP, Paulissen SMJ, de Bruijn MJW, Rip J, Lukkes M, et al. . Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease. Arthritis Rheumatol (2017) 69(6):1313–24. doi: 10.1002/art.40059
    1. Shen L, Suresh L, Lindemann M, Xuan J, Kowal P, Malyavantham K, et al. . Novel Autoantibodies in Sjogren’s Syndrome. Clin Immunol (2012) 145(3):251–5. doi: 10.1016/j.clim.2012.09.013
    1. Bowman S, Everett C, Bombardieri M, Busch R, Emery P, Hall F, et al. . Preliminary Results of a Double-Blind Randomised Trial of Rituximab Anti-B-Cell Therapy in Patients With Primary Sjogrens Syndrome. Arthritis Rheumatol (2015) 67. doi: 10.1002/art.39448
    1. Nore BF, Vargas L, Mohamed AJ, Branden LJ, Backesjo CM, Islam TC, et al. . Redistribution of Bruton’s Tyrosine Kinase by Activation of Phosphatidylinositol 3-Kinase and Rho-Family GTPases. Eur J Immunol (2000) 30(1):145–54. doi: 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>;2-0
    1. Tomlinson MG, Woods DB, McMahon M, Wahl MI, Witte ON, Kurosaki T, et al. . A Conditional Form of Bruton’s Tyrosine Kinase Is Sufficient to Activate Multiple Downstream Signaling Pathways via PLC Gamma 2 in B Cells. BMC Immunol (2001) 2:4. doi: 10.1186/1471-2172-2-4
    1. Mukhopadhyay S, Ramars AS, Dash D. Bruton’s Tyrosine Kinase Associates With the Actin-Based Cytoskeleton in Activated Platelets. J Cell Biochem (2001) 81(4):659–65. doi: 10.1002/jcb.1088
    1. Sharma S, Orlowski G, Song W. Btk Regulates B Cell Receptor-Mediated Antigen Processing and Presentation by Controlling Actin Cytoskeleton Dynamics in B Cells. J Immunol (2009) 182(1):329–39. doi: 10.4049/jimmunol.182.1.329
    1. Liu C, Miller H, Hui KL, Grooman B, Bolland S, Upadhyaya A, et al. . A Balance of Bruton’s Tyrosine Kinase and SHIP Activation Regulates B Cell Receptor Cluster Formation by Controlling Actin Remodeling. J Immunol (2011) 187(1):230–9. doi: 10.4049/jimmunol.1100157
    1. Zarrin AA, Bao K, Lupardus P, Vucic D. Kinase Inhibition in Autoimmunity and Inflammation. Nat Rev Drug Discov (2021) 20(1):39–63. doi: 10.1038/s41573-020-0082-8
    1. Yu P, Constien R, Dear N, Katan M, Hanke P, Bunney TD, et al. . Autoimmunity and Inflammation Due to a Gain-of-Function Mutation in Phospholipase C Gamma 2 That Specifically Increases External Ca2+ Entry. Immunity (2005) 22(4):451–65. doi: 10.1016/j.immuni.2005.01.018
    1. De Klerck B, Geboes L, Hatse S, Kelchtermans H, Meyvis Y, Vermeire K, et al. . Pro-Inflammatory Properties of Stromal Cell-Derived Factor-1 (CXCL12) in Collagen-Induced Arthritis. Arthritis Res Ther (2005) 7(6):R1208–20. doi: 10.1186/ar1806
    1. Amft N, Bowman SJ. Chemokines and Cell Trafficking in Sjogren’s Syndrome. Scand J Immunol (2001) 54(1-2):62–9. doi: 10.1046/j.1365-3083.2001.00970.x
    1. Barone F, Bombardieri M, Rosado MM, Morgan PR, Challacombe SJ, De Vita S, et al. . CXCL13, CCL21, and CXCL12 Expression in Salivary Glands of Patients With Sjogren’s Syndrome and MALT Lymphoma: Association With Reactive and Malignant Areas of Lymphoid Organization. J Immunol (2008) 180(7):5130–40. doi: 10.4049/jimmunol.180.7.5130
    1. Hernandez-Molina G, Michel-Peregrina M, Hernandez-Ramirez DF, Sanchez-Guerrero J, Llorente L. Chemokine Saliva Levels in Patients With Primary Sjogren’s Syndrome, Associated Sjogren’s Syndrome, Pre-Clinical Sjogren’s Syndrome and Systemic Autoimmune Diseases. Rheumatol (Oxford) (2011) 50(7):1288–92. doi: 10.1093/rheumatology/ker019
    1. Kanbe K, Takagishi K, Chen Q. Stimulation of Matrix Metalloprotease 3 Release From Human Chondrocytes by the Interaction of Stromal Cell-Derived Factor 1 and CXC Chemokine Receptor 4. Arthritis Rheum (2002) 46(1):130–7. doi: 10.1002/1529-0131(200201)46:1<130::AID-ART10020>;2-D
    1. Grassi F, Cristino S, Toneguzzi S, Piacentini A, Facchini A, Lisignoli G. CXCL12 Chemokine Up-Regulates Bone Resorption and MMP-9 Release by Human Osteoclasts: CXCL12 Levels Are Increased in Synovial and Bone Tissue of Rheumatoid Arthritis Patients. J Cell Physiol (2004) 199(2):244–51. doi: 10.1002/jcp.10445
    1. Joven B, Gonzalez N, Aguilar F, Santiago B, Galindo M, Alcami J, et al. . Association Between Stromal Cell-Derived Factor 1 Chemokine Gene Variant and Radiographic Progression of Rheumatoid Arthritis. Arthritis Rheum (2005) 52(1):354–6. doi: 10.1002/art.20743
    1. Hansen IB, Ellingsen T, Hornung N, Poulsen JH, Lottenburger T, Stengaard-Pedersen K. Plasma Level of CXC-Chemokine CXCL12 Is Increased in Rheumatoid Arthritis and Is Independent of Disease Activity and Methotrexate Treatment. J Rheumatol (2006) 33(9):1754–9.
    1. Brassat D, Motsinger AA, Caillier SJ, Erlich HA, Walker K, Steiner LL, et al. . Multifactor Dimensionality Reduction Reveals Gene-Gene Interactions Associated With Multiple Sclerosis Susceptibility in African Americans. Genes Immun (2006) 7(4):310–5. doi: 10.1038/sj.gene.6364299
    1. McCandless EE, Piccio L, Woerner BM, Schmidt RE, Rubin JB, Cross AH, et al. . Pathological Expression of CXCL12 at the Blood-Brain Barrier Correlates With Severity of Multiple Sclerosis. Am J Pathol (2008) 172(3):799–808. doi: 10.2353/ajpath.2008.070918
    1. Luskova P, Draber P. Modulation of the Fcepsilon Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases. Curr Pharm Des (2004) 10(15):1727–37. doi: 10.2174/1381612043384538
    1. Kuehn HS, Swindle EJ, Kim MS, Beaven MA, Metcalfe DD, Gilfillan AM. The Phosphoinositide 3-Kinase-Dependent Activation of Btk Is Required for Optimal Eicosanoid Production and Generation of Reactive Oxygen Species in Antigen-Stimulated Mast Cells. J Immunol (2008) 181(11):7706–12. doi: 10.4049/jimmunol.181.11.7706
    1. Ishmael S, MacGlashan D., Jr. Early Signal Protein Expression Profiles in Basophils: A Population Study. J Leukoc Biol (2009) 86(2):313–25. doi: 10.1189/jlb.1208724
    1. MacGlashan D, Jr., Honigberg LA, Smith A, Buggy J, Schroeder JT. Inhibition of IgE-Mediated Secretion From Human Basophils With a Highly Selective Bruton’s Tyrosine Kinase, Btk, Inhibitor. Int Immunopharmacol (2011) 11(4):475–9. doi: 10.1016/j.intimp.2010.12.018
    1. Cenni B, Gutmann S, Gottar-Guillier M. BMX and Its Role in Inflammation, Cardiovascular Disease, and Cancer. Int Rev Immunol (2012) 31(2):166–73. doi: 10.3109/08830185.2012.663838
    1. Gottar-Guillier M, Dodeller F, Huesken D, Iourgenko V, Mickanin C, Labow M, et al. . The Tyrosine Kinase BMX Is an Essential Mediator of Inflammatory Arthritis in a Kinase-Independent Manner. J Immunol (2011) 186(10):6014–23. doi: 10.4049/jimmunol.1002813
    1. Qiu L, Wang F, Liu S, Chen XL. Current Understanding of Tyrosine Kinase BMX in Inflammation and Its Inhibitors. Burns Trauma (2014) 2(3):121–4. doi: 10.4103/2321-3868.135483
    1. Ekman N, Lymboussaki A, Vastrik I, Sarvas K, Kaipainen A, Alitalo K. Bmx Tyrosine Kinase Is Specifically Expressed in the Endocardium and the Endothelium of Large Arteries. Circulation (1997) 96(6):1729–32. doi: 10.1161/01.CIR.96.6.1729
    1. Holopainen T, Rasanen M, Anisimov A, Tuomainen T, Zheng W, Tvorogov D, et al. . Endothelial Bmx Tyrosine Kinase Activity Is Essential for Myocardial Hypertrophy and Remodeling. Proc Natl Acad Sci USA (2015) 112(42):13063–8. doi: 10.1073/pnas.1517810112
    1. Liu T, Li Y, Su H, Zhang H, Jones D, Zhou HJ, et al. . Nuclear Localization of the Tyrosine Kinase BMX Mediates VEGFR2 Expression. J Cell Mol Med (2020) 24(1):126–38. doi: 10.1111/jcmm.14663
    1. Rajantie I, Ekman N, Iljin K, Arighi E, Gunji Y, Kaukonen J, et al. . Bmx Tyrosine Kinase has a Redundant Function Downstream of Angiopoietin and Vascular Endothelial Growth Factor Receptors in Arterial Endothelium. Mol Cell Biol (2001) 21(14):4647–55. doi: 10.1128/MCB.21.14.4647-4655.2001
    1. Palmer CD, Mutch BE, Workman S, McDaid JP, Horwood NJ, Foxwell BM. Bmx Tyrosine Kinase Regulates TLR4-Induced IL-6 Production in Human Macrophages Independently of P38 MAPK and NFkapp}B Activity. Blood (2008) 111(4):1781–8. doi: 10.1182/blood-2007-07-102343
    1. Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, et al. . Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. J Med Chem (2019) 62(17):7923–40. doi: 10.1021/acs.jmedchem.9b00687
    1. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. . Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib. N Engl J Med (2014) 370(24):2286–94. doi: 10.1056/NEJMoa1400029
    1. Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. . BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol (2017) 35(13):1437–43. doi: 10.1200/JCO.2016.70.2282
    1. Quinquenel A, Fornecker LM, Letestu R, Ysebaert L, Fleury C, Lazarian G, et al. . Prevalence of BTK and PLCG2 Mutations in a Real-Life CLL Cohort Still on Ibrutinib After 3 Years: A FILO Group Study. Blood (2019) 134(7):641–4. doi: 10.1182/blood.2019000854
    1. Estupinan HY, Bouderlique T, He C, Berglof A, Gupta D, Saher O, et al. . Novel Mouse Model Resistant to Irreversible BTK Inhibitors: A Tool Identifying New Therapeutic Targets and Side Effects. Blood Adv (2020) 4(11):2439–50. doi: 10.1182/bloodadvances.2019001319
    1. Giudice V, Vecchione C, Selleri C. Cardiotoxicity of Novel Targeted Hematological Therapies. Life (Basel) (2020) 10(12):344. doi: 10.3390/life10120344
    1. Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, et al. . Outcomes of CLL Patients Treated With Sequential Kinase Inhibitor Therapy: A Real World Experience. Blood (2016) 128(18):2199–205. doi: 10.1182/blood-2016-05-716977
    1. Isaac K, Mato AR. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data. Cancer Manag Res (2020) 12:2079–85. doi: 10.2147/CMAR.S219570
    1. Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien S, Constantine S, et al. . First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Eur Hematol Association: Presidential Symposium. (2011). Poster LB1900. Available at: .
    1. Paydas S. Management of Adverse Effects/Toxicity of Ibrutinib. Crit Rev Oncol Hematol (2019) 136:56–63. doi: 10.1016/j.critrevonc.2019.02.001
    1. Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, et al. . Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor With a Differentiated Selectivity and In Vivo Pot Ip789ency Profile. J Pharmacol Exp Ther (2017) 363(2):240–52. doi: 10.1124/jpet.117.242909
    1. Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): A Selective Second-Generation BTK Inhibitor. J Hematol Oncol (2016) 9:21. doi: 10.1186/s13045-016-0250-9
    1. Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, et al. . Ibrutinib Treatment Affects Collagen and Von Willebrand Factor-Dependent Platelet Functions. Blood (2014) 124(26):3991–5. doi: 10.1182/blood-2014-06-583294
    1. Gratacap MP, Martin V, Valera MC, Allart S, Garcia C, Sie P, et al. . The New Tyrosine-Kinase Inhibitor and Anticancer Drug Dasatinib Reversibly Affects Platelet Activation In Vitro and In Vivo. Blood (2009) 114(9):1884–92. doi: 10.1182/blood-2009-02-205328
    1. Chen J, Kinoshita T, Gururaja T, Sukbuntherng J, James D, Lu D, et al. . The Effect of Bruton’s Tyrosine Kinase (BTK) Inhibitors on Collagen-Induced Platelet Aggregation, BTK, and Tyrosine Kinase Expressed in Hepatocellular Carcinoma (TEC). Eur J Haematol (2018) 101(5):604–12. doi: 10.1111/ejh.13148
    1. . A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE). Bethesda (MD): National Library of Medicine (US) (2016). Available at: .
    1. Lewis KL, Cheah CY. Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies. J Pers Med (2021) 11(8):764. doi: 10.3390/jpm11080764

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi